Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals

Abstract Background Amyloid pathology, which is one of the characteristics of Alzheimer’s disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ1–42 is evident in AD, and the CS...

Full description

Bibliographic Details
Main Authors: Sylvain Lehmann, Julien Dumurgier, Xavier Ayrignac, Cecilia Marelli, Daniel Alcolea, Juan Fortea Ormaechea, Eric Thouvenot, Constance Delaby, Christophe Hirtz, Jérôme Vialaret, Nelly Ginestet, Elodie Bouaziz-Amar, Jean-Louis Laplanche, Pierre Labauge, Claire Paquet, Alberto Lleo, Audrey Gabelle, for the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Amyloid peptides
Tau proteins
Biomarkers
Cerebrospinal fluid (CSF)
Online Access:http://link.springer.com/article/10.1186/s13195-020-00696-1

Internet

http://link.springer.com/article/10.1186/s13195-020-00696-1

Similar Items